{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:28:52Z","timestamp":1793744932826,"version":"4.6.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.gore.2026.102210","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:34:28Z","timestamp":1788910468000},"page":"102210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Temozolomide and olaparib for the treatment of an ARID1A-mutated uterine carcinosarcoma: A case report"],"prefix":"10.1016","volume":"67","author":[{"given":"Chrissy","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Abozenah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaagn","family":"Andikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Kohut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102210_bb0005","article-title":"Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer","volume":"6","author":"Bando","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"7","key":"10.1016\/j.gore.2026.102210_bb0010","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djy085","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"110","author":"Hoppe","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"25","key":"10.1016\/j.gore.2026.102210_bb0015","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1200\/JCO.23.00402","article-title":"Phase II study of olaparib and temozolomide for advanced uterine leiomyosarcoma (NCI protocol 10250)","volume":"41","author":"Ingham","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2026.102210_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26104644","article-title":"ARID1A and its impact across the hallmarks of cancer","volume":"26","author":"Kearns","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.gore.2026.102210_bb0025","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","article-title":"ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity","volume":"187","author":"Maxwell","year":"2024","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.gore.2026.102210_bb0030","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1007\/s43032-024-01585-w","article-title":"ARID1A in Gynecologic precancers and cancers","volume":"31","author":"Morgan","year":"2024","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.gore.2026.102210_bb0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2023.12.025","article-title":"Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies","volume":"182","author":"Recio","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102210_bb0040","article-title":"Cancer antigen 125 is associated with disease status in uterine carcinosarcoma","volume":"7","author":"Ross","year":"2019","journal-title":"SAGE Open Med."},{"issue":"15","key":"10.1016\/j.gore.2026.102210_bb0045","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.gore.2026.102210_bb0050","doi-asserted-by":"crossref","first-page":"7076","DOI":"10.1038\/s41467-024-51090-6","article-title":"The Fanconi anemia core complex promotes CtIP-dependent end resection to drive homologous recombination at DNA double-strand breaks","volume":"15","author":"van de Kooij","year":"2024","journal-title":"Nat. Commun."},{"issue":"16_suppl","key":"10.1016\/j.gore.2026.102210_bb0055","doi-asserted-by":"crossref","first-page":"11507","DOI":"10.1200\/JCO.2025.43.16_suppl.11507","article-title":"Alliance A092104: a randomized phase 2\/3 study of olaparib plus temozolomide versus investigator\u2019s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy","volume":"43","author":"Van Tine","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2026.102210_bb0060","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4161\/cbt.28411","article-title":"The emerging roles of ARID1A in tumor suppression","volume":"15","author":"Wu","year":"2014","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"10.1016\/j.gore.2026.102210_bb0065","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2025.13660","article-title":"Potential role of Fanconi anemia pathway in the pathogenesis of endometrial cancer (review)","volume":"32","author":"Yao","year":"2025","journal-title":"Mol. Med. Rep."},{"issue":"16","key":"10.1016\/j.gore.2026.102210_bb0070","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-22-3646","article-title":"Temozolomide sensitizes ARID1A-mutated cancers to PARP inhibitors","volume":"83","author":"Yu","year":"2023","journal-title":"Cancer Res."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:02:05Z","timestamp":1793743325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":14,"alternative-id":["S2352578926001906"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102210","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temozolomide and olaparib for the treatment of an ARID1A-mutated uterine carcinosarcoma: A case report","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102210"}}